Bromodomain Inhibitor Design via BD2 Selectivity and Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective inhibitors for the BET family of bromodomains, which are crucial for regulating gene transcription, as existing compounds do not selectively inhibit the binding of these domains to acetylated lysine residues, particularly through the Binding Domain 2 (BD2).
Innovation Solution
Development of a novel compound of formula (I) and its pharmaceutically acceptable salts, which selectively inhibit the binding of BET family bromodomains via the BD2 domain, disrupting the interaction with acetylated lysine residues, thereby modulating gene transcription.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds are used to inhibit BET family bromodomains, then some level of inhibition may be achieved, but selective inhibition of BD2 domain binding to acetylated lysine residues is not achieved
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features that target the BD2 domain's acetylated lysine binding pocket. The compounds contain a hydrophobic group that interacts with the aromatic cage of the bromodomain, and a basic nitrogen that forms a salt bridge with aspartate residue D112, providing selective inhibition of BD2 over other bromodomain family members.
Solution Approach 2:
The patent employs parameter changes by optimizing the chemical structure of the compounds, specifically varying the hydrophobic group (aryl, heteroaryl, or alkyl), the linker (amino, oxy, or thio), and the basic nitrogen substituent to achieve optimal binding affinity and selectivity for the BD2 domain while maintaining pharmacological properties.
2Reliability
If compounds are designed to selectively inhibit BD2 domain, then specific therapeutic effects are achieved, but the complexity of achieving selective binding increases
Solution Approach 1:
The patent applies segmentation by dividing the compound into three distinct functional segments: a hydrophobic group (segment 1) that binds to the aromatic cage, a linker (segment 2) that connects the hydrophobic group to the basic nitrogen, and a basic nitrogen with substituents (segment 3) that forms the salt bridge with D112. This segmentation allows each part to be optimized independently for selectivity and activity.
Solution Approach 2:
The patent uses the linker (amino, oxy, or thio) as an intermediary that connects the hydrophobic group to the basic nitrogen, allowing proper spatial positioning and orientation of the two key binding elements within the BD2 domain pocket, thereby facilitating selective binding without requiring overly complex molecular structures.
Data Source
AI summary
The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.